- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00425425
Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer
Neoadjuvant Radiochemotherapy in Local Advanced Squamous Cell Carcinoma of the Esophagus With Weekly Cetuximab Plus Oxaliplatin Plus Continuous IV. 5-FU and Conventional Fractionated External Multi-Field Irradiation up to 45 Gray. A Phase I/II Study
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cetuximab, chemotherapy, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase I/II trial is studying the side effects and best dose of oxaliplatin and fluorouracil when given together with cetuximab and radiation therapy and to see how well they work in treating patients with stage II or stage III esophageal cancer.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of oxaliplatin and fluorouracil when administered with cetuximab and radiotherapy in patients with stage II or III squamous cell carcinoma of the esophagus. (Phase I)
- Determine the response rate in patients treated with this regimen. (Phase II)
Secondary
- Determine the toxicity of this regimen in these patients.
- Determine the postoperative complication rate and lethality in patients treated with this regimen.
- Determine the R0 resection rate in patients treated with this regimen.
- Determine the overall survival of patients treated with this regimen.
- Determine the event-free survival of patients treated with this regimen.
- Determine the metabolic response rate in patients treated with this regimen.
OUTLINE: This is a phase I, dose-escalation study of oxaliplatin and fluorouracil followed by an open-label, phase II study.
- Phase I: Patients receive cetuximab IV over 60-90 minutes on days -15, -8, 1, 8, 15, 22, and 29; oxaliplatin IV over 120 minutes on days 1, 8, 22, and 29; and fluorouracil IV continuously on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients then undergo radical esophagectomy 29-42 days after the completion of chemoradiotherapy.
Cohorts of 3-6 patients receive escalating doses of oxaliplatin and fluorouracil until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Phase II: Patients receive oxaliplatin and fluorouracil as in phase I at the MTD determined in phase I. Patients also receive cetuximab and undergo radiotherapy and radical esophagectomy as in phase I.
After completion of study therapy, patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 43 patients will be accrued for this study.
Studietype
Registrering (Forventet)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Berlin, Tyskland, D-13353
- Charite University Hospital - Campus Virchow Klinikum
-
Marburg, Tyskland, D-35033
- Universitaetsklinikum Giessen und Marburg GmbH - Marburg
-
Munich, Tyskland, D-81675
- Klinikum Rechts der Isar - Technische Universitaet Muenchen
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically confirmed squamous cell carcinoma of the esophagus, meeting the following criteria:
- Locally advanced disease (T3-T4, N0-N+ [T2, N0 for cervical esophageal carcinoma])
- Potentially resectable disease
- No distant metastases (M1b)
- No tumor infiltration of the tracheobronchial system
- Bartels preoperative risk analysis < 22
PATIENT CHARACTERISTICS:
- ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%
- Creatinine ≤ 1.5 mg/dL OR creatinine clearance > 60 mL/min
- Bilirubin ≤ 1.5 mg/dL
- ALT and AST ≤ 2 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2 times ULN
- WBC ≥ 3,000/mm³
- Granulocyte count ≥ 2,000/mm³
- Platelet count ≥ 100,000/mm³
- No pre-existing polyneuropathy > grade 1
- No active uncontrolled infection
- PaO_2 ≥ 60 mm Hg on room air
- FEV_1 ≥ 60% of normal
- No New York Heart Association class II-IV cardiac insufficiency
- Ejection fraction ≥ 35%
- No angina pectoris (at rest or under stress) unexplained by interventional cardiology
- No myocardial infarction within the past 6 months
- No histologically confirmed liver cirrhosis
- No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanomatous skin cancer
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy
- No prior radiotherapy to the thorax region
- No current esophageal stent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Maximum tolerated dose of oxaliplatin and fluorouracil (Phase I)
|
Response rate (histological remission) (Phase II)
|
Sekundære resultatmål
Resultatmål |
---|
Total overlevelse
|
Begivenhetsfri overlevelse
|
R0 reseksjonsrate
|
Toxicity as measured by NCI-CTC criteria
|
Postoperative complication rate and lethality
|
Metabolic response rate
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Florian Lordick, MD, Technical University of Munich
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Neoplasmer i hode og nakke
- Esophageal sykdommer
- Neoplasmer i spiserøret
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, immunologiske
- Fluorouracil
- Oksaliplatin
- Cetuximab
Andre studie-ID-numre
- CDR0000516821
- KRDI-TUM-OE7-432-LOR-0033-I
- EU-20658
- EUDRACT-2006-001097-24
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kreft i spiserøret
-
Johns Hopkins UniversityTilbaketrukketEsophageal perforering | Esophageal fistel | Esophageal fortrengninger | Esophageal lekkasje | Endostitch | Esophageal stentForente stater
-
Mayo ClinicRekrutteringOpioid-indusert esophageal dysfunksjonForente stater
-
Mayo ClinicFullførtEsophageal dilatasjon | Ildfast benign esophageal strikturForente stater
-
Mayo ClinicAvsluttetAchalasia | Esophageal Achalasia | Achalasia, esophagealForente stater
-
The Methodist Hospital Research InstituteFullførtEsophageal eller gastrisk perforering | Esophageal eller gastrisk lekkasjerForente stater
-
Federal University of São PauloUkjentEsophageal innsnevring | Etsende esophageal striktur | Peptisk esophageal striktur | Post-kirurgisk esofageal strikturBrasil
-
Zagazig UniversityFullførtIatrogen esophageal perforeringEgypt
-
Vanderbilt University Medical CenterAmenity Health, Inc.Avsluttet
-
Radboud University Medical CenterUkjentGodartet esophageal strikturNederland
-
Nagasaki UniversityUkjentEsophageal anastomotisk strikturJapan
Kliniske studier på fluorouracil
-
Sun Yat-sen UniversityZhejiang Cancer Hospital; Fudan University; Peking University Cancer Hospital... og andre samarbeidspartnereUkjentNasofaryngealt karsinomKina
-
CStone PharmaceuticalsAktiv, ikke rekrutterendeIkke-opererbart lokalt avansert, tilbakevendende eller metastatisk esofageal plateepitelkarsinomKina
-
Sun Yat-sen UniversityUkjent
-
The Netherlands Cancer InstituteFullført
-
Actavis Inc.FullførtAktinisk keratoseForente stater
-
Hokkaido Gastrointestinal Cancer Study GroupHokkaido University HospitalFullført
-
The Netherlands Cancer InstituteFullført
-
Hong Kong Nasopharyngeal Cancer Study Group LimitedThe Hong Kong Anti-Cancer Society; hong Kong Cancer FundFullført
-
Boston UniversityRekrutteringOverfladisk basalcellekarsinom | Plateepitelkarsinom in situForente stater
-
Medical Research CouncilFullførtBlærekreft | Overgangscellekreft i nyrebekkenet og urinlederen | Kreft i urinrøretCanada, Storbritannia, Norge, New Zealand, Nederland, Sør-Afrika, Brasil, Finland